Clinical trials: sponsored by Amgen
Secondary Hyperparathyroidism, End Stage Renal Disease
A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients
This 6 month long study will assess an investigational medication for patients on dialysis with secondary hyperparathyroidism. The study will look at the effects on parathyroid hormone, calcium and phosphorus levels.
- Trial name
- NCT00037635
- Testing
- AMG 073
- Volunteers
- 400 people
- Sponsor
- Amgen
Secondary Hyperparathyroidism, End Stage Renal Disease
A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis
This 6 month study will assess an investigational medication for patients on dialysis with secondary hyperparathyroidism. The study will look at the effects on parathyroid hormone, calcium and phosphorus levels.
- Trial name
- NCT00042653
- Testing
- AMG 073
- Volunteers
- 380 people
- Sponsor
- Amgen
Hyperparathyroidism, Primary
A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism
This multicenter, open-label, single-arm, extension study was designed to evaluate long-term tolerability, safety, and efficacy of cinacalcet. Subjects were enrolled immediately after they completed the parent study, 990120.
- Trial name
- NCT00936988
- Testing
- cinacalcet
- Volunteers
- 45 people
- Sponsor
- Amgen
Anemia, Cancer
Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer
The purpose of this study is to evaluate the efficacy of darbepoetin alfa versus placebo in reducing the occurrences of red blood cell transfusions in subjects with anemia of cancer who are not receiving chemotherapy.
- Trial name
- NCT00091858
- Testing
- Darbepoetin Alfa
- Volunteers
- 1,000 people
- Sponsor
- Amgen
Kidney Disease, Chronic Kidney Disease
Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis
The purpose of this study is to evaluate the efficacy and safety of cinacalcet compared with placebo in patients with stage 3 and 4 Chronic Kidney Disease (CKD).
- Trial name
- NCT00094484
- Testing
- Cinacalcet HCl
- Volunteers
- 400 people
- Sponsor
- Amgen
Pre-dialysis, End Stage Renal Disease
NESP Pediatric Study
Open-label, randomized study of NESP in pediatric subjects 18 years of age or younger. Subjects will receive study drug (NESP or rHuEPO) for 28 weeks after a 2 week screening and baseline period.
- Trial name
- NCT00527137
- Testing
- darbepoetin alfa, rHuEPO
- Volunteers
- 120 people
- Sponsor
- Amgen
Anemia, Non-Myeloid Malignancies
Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy
The purpose of this study is to compare the effect of darbepoetin alfa administered in a weight based versus fixed dosing for the treatment of anemia in subjects with non-myeloid malignancies receiving multicycle chemotherapy.
- Conditions
- Anemia, Non-Myeloid Malignancies, Cancer
- Trial name
- NCT00111462
- Testing
- Darbepoetin alfa
- Sponsor
- Amgen
Gastrointestinal Cancer
Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs)
This study will determine the safety and effectiveness of AMG 706 in patients with advanced GIST.
- Trial name
- NCT00089960
- Testing
- AMG 706
- Volunteers
- 138 people
- Sponsor
- Amgen
Anemia, Non-Myeloid Malignancies
A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy
The purpose of this study is to evaluate the efficacy of darbepoetin alfa as 500ug once every 3 weeks to show that the dose and schedule are not inferior to darbepoetin alfa administered as 2.25ug/kg once per week in the…
- Trial name
- NCT00118638
- Testing
- Darbepoetin alfa - 2.25 mcg/kg, Darbepoetin alfa - 500mcg
- Volunteers
- 705 people
- Sponsor
- Amgen
Anemia
Study of Transplant Related Anemia Treated With Aranesp® (STRATA)
The purpose of this study was to evaluate Aranesp® administered subcutaneously (SC) to maintain hemoglobin (Hb) levels in renal transplant recipients.
- Trial name
- NCT00117065
- Testing
- Aranesp®
- Sponsor
- Amgen
Psoriasis
Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects
The purpose of this study is to evaluate the safety and tolerability of long-term administration of etanercept in adults with psoriasis who have participated in previous etanercept psoriasis studies.
- Trial name
- NCT00111436
- Testing
- Etanercept
- Volunteers
- 912 people
- Sponsor
- Amgen
Anemia, Non-Myeloid Malignancies
Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa
The purpose of this study is to develop a functional capacity screening tool (FCST) that estimates at baseline the functional capacity of anemic subjects with nonmyeloid malignancies receiving multicycle chemotherapy.
- Trial name
- NCT00540696
- Testing
- darbepoetin alfa
- Volunteers
- 300 people
- Sponsor
- Amgen
Rheumatoid Arthritis
Treatment for Subjects With Active Rheumatoid Arthritis (RA)
The purpose of this study is to assess the safety of etanercept liquid administered once weekly to subjects with RA.
- Trial name
- NCT00110903
- Testing
- Etanercept Liquid
- Sponsor
- Amgen
Anemia, Secondary Hyperparathyroidism
A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD)
The purpose of this study is to show that the use of cinacalcet in patients with End Stage Renal Disease can help achieve NKF K/DOQI targets for both serum calcium and calcium phosphorous product.
- Trial name
- NCT00431496
- Testing
- Cinacalcet
- Volunteers
- 71 people
- Sponsor
- Amgen
Diabetes Mellitus
Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects
This is a phase 1, randomized, double-blind, placebo-controlled, 2-way crossover study to evaluate the effect of AMG 151 on 24-hour ambulatory blood pressure and glucose levels in subjects with type 2 diabetes mellitus who are on…
- Trial name
- NCT01755442
- Testing
- AMG 151
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Amgen
Systemic Lupus Erythematosus
A Study of AMG 557 in Adults With Systemic Lupus Erythematosus
This is a Phase 1, randomized, placebo-controlled, double-blind, dose-escalation study of repeat SC doses of AMG 557 in adults with Systemic Lupus Erythematosus.
- Trial name
- NCT00774943
- Testing
- AMG 557
- Where
- 12 sites in United States, Canada
- Volunteers
- 58 people
- Sponsor
- Amgen
Psoriasis
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Psoriasis
The purpose of this study is to assess the safety, tolerability, immunogenicity, and clinical effects of AMG 811 following single subcutaneous dose administration in subjects with moderate to severe psoriasis.
- Trial name
- NCT01510951
- Where
- 4 sites in Australia, New Zealand
- Volunteers
- 9 people
- Sponsor
- Amgen
Diabetes Mellitus
Single Ascending Dose Trial in Patients With Type 2 Diabetes
The purpose of this study is to determine whether AMG 876 is safe and well tolerated in subjects with type 2 diabetes.
- Trial name
- NCT01492465
- Testing
- AMG 876
- Where
- 3 sites in United States
- Volunteers
- 47 people
- Sponsor
- Amgen
Postmenopausal Osteoporosis
A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates
This is a multi-center, randomized, open-label, parallel group, study being conducted in the United States and in Europe in postmenopausal women.
- Trial name
- NCT00936897
- Testing
- Ibandronate, Denosumab
- Volunteers
- 833 people
- Sponsor
- Amgen
Schizophrenia
First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia
The purpose of this study is to assess the safety and tolerability of AMG 579 following a single oral dose administration in healthy subjects (Part A) and in patients with schizophrenia or stable schizoaffective disorder (Part…
- Trial name
- NCT01568203
- Testing
- AMG 579
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.